Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Evo Alemao"'
Autor:
Jonathan I. Silverberg, Feifei Yang, Evo Alemao, Jing Zhao, Concetta Crivera, Hetal V. Patel, Iris Lin, Aaron R. Mangold
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1206-1211 (2024)
Abstract Background The potential association of long‐term oral corticosteroid (OCS) use with adverse events (AEs) in patients with bullous pemphigoid (BP) is not well characterized in a real‐world setting. Objectives To evaluate the effect of OC
Externí odkaz:
https://doaj.org/article/16ee0fb30da34575b66759ff2cd9c7a3
Autor:
Irina Murakhovskaya, Concetta Crivera, Ann Leon, Evo Alemao, Vamshi Ruthwik Anupindi, Mitch Dekoven, Victoria Divino, Iris Lin, Cathye Shu, Tarek Ebrahim
Publikováno v:
HemaSphere, Vol 7, p e04294a8 (2023)
Externí odkaz:
https://doaj.org/article/3b6977f268c441db800bd0f7087b13f7
Autor:
Patricia Katz, Sofia Pedro, Evo Alemao, Jinoos Yazdany, Maria Dall'Era, Laura Trupin, Stephanie Rush, Kaleb Michaud
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 1, Pp 53-60 (2020)
Objective Examinations of Patient‐Reported Outcomes Measurement Information System (PROMIS) measures in adult systemic lupus erythematosus (SLE) have provided support for their cross‐sectional validity in SLE. We estimated responsiveness to chang
Externí odkaz:
https://doaj.org/article/b7974e96f8204eeaad5bcce2b5fd6512
Autor:
Candace H. Feldman, Kazuki Yoshida, Chang Xu, Michelle L. Frits, Nancy A. Shadick, Michael E. Weinblatt, Sean E. Connolly, Evo Alemao, Daniel H. Solomon
Publikováno v:
ACR Open Rheumatology, Vol 1, Iss 9, Pp 552-559 (2019)
Objective Previous attempts to estimate rheumatoid arthritis (RA) disease activity using claims data only did not yield high performance. We aimed to assess whether supplementing claims data with readily available electronic medical record (EMR) data
Externí odkaz:
https://doaj.org/article/59c0337c41b74384b59f717579281585
Autor:
Roy Fleischmann, Michael Weinblatt, Harris Ahmad, Michael A. Maldonado, Evo Alemao, June Ye, Michael Schiff
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 4, Pp 559-571 (2019)
Abstract Introduction Patients with rheumatoid arthritis (RA) with poor prognostic factors, such as seropositivity for anti-citrullinated protein antibodies and early erosions, may benefit from early intensive treatment. However, information to guide
Externí odkaz:
https://doaj.org/article/bacb69c25d2542d1835b46507de62903
Autor:
Denis Choquette, Louis Bessette, Evo Alemao, Boulos Haraoui, Roelien Postema, Jean-Pierre Raynauld, Louis Coupal
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi)
Externí odkaz:
https://doaj.org/article/e39399247f704d24b4943cdaec2f0e0f
Autor:
Leslie R. Harrold, Heather J. Litman, Sean E. Connolly, Evo Alemao, Sheila Kelly, Sabrina Rebello, Winnie Hua, Joel M. Kremer
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 2, Pp 217-230 (2019)
Abstract Introduction Anti-citrullinated protein antibodies (ACPAs) are highly specific serological biomarkers that are indicative of a poor prognosis in patients with rheumatoid arthritis (RA). The effectiveness of biologic disease-modifying antirhe
Externí odkaz:
https://doaj.org/article/812cba2a5c4548318fedf2a8c36e6960
Autor:
Vibeke Strand, Evo Alemao, Thomas Lehman, Alyssa Johnsen, Subhashis Banerjee, Harris A. Ahmad, Philip J. Mease
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Abstract Background To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). Methods Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early
Externí odkaz:
https://doaj.org/article/3f7b9386ce994ffb83cc3434ef5ac956
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Introduction: For patients with rheumatoid arthritis (RA) with an inadequate response to tumor necrosis factor inhibitors (TNFi), main options include cycling onto a different TNFi or switching to a biologic/targeted synthetic disease-modifying antir
Externí odkaz:
https://doaj.org/article/8fc86b9686c940f887976a3915ca4391
Autor:
Evo Alemao, Maiwenn J Al, Annelies A Boonen, Matthew D Stevenson, Suzanne M M Verstappen, Kaleb Michaud, Michael E Weinblatt, Maureen P M H Rutten-van Mölken
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205013 (2018)
The objective of this study was to evaluate current approaches to economic modeling in rheumatoid arthritis (RA) and propose a new conceptual model for evaluation of the cost-effectiveness of RA interventions. We followed recommendations from the Int
Externí odkaz:
https://doaj.org/article/4187b2f613c94bdf83eddab2af8e7526